NasdaqGS - Delayed Quote USD
Poseida Therapeutics, Inc. (PSTX)
At close: November 1 at 4:00 PM EDT
After hours: November 1 at 4:03 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -0.41 | -0.41 | -1.41 | -1.84 |
| Low Estimate | -0.48 | -0.51 | -1.57 | -2.38 |
| High Estimate | -0.33 | -0.28 | -1.25 | -1.44 |
| Year Ago EPS | -0.35 | -0.27 | -1.37 | -1.41 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 16.27M | 16.27M | 86.6M | 43.33M |
| Low Estimate | 15M | 15M | 84.1M | 10M |
| High Estimate | 18.8M | 18.8M | 91.6M | 70M |
| Year Ago Sales | 9.35M | 25M | 64.7M | 86.6M |
| Sales Growth (year/est) | 74.00% | -34.90% | 33.80% | -50.00% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.29 | -0.39 | -0.42 | -0.41 |
| EPS Actual | -0.35 | -0.27 | -0.25 | -0.32 |
| Difference | -0.06 | 0.12 | 0.17 | 0.09 |
| Surprise % | -20.70% | 30.80% | 40.50% | 22.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.41 | -0.41 | -1.41 | -1.84 |
| 7 Days Ago | -0.41 | -0.41 | -1.41 | -1.84 |
| 30 Days Ago | -0.41 | -0.41 | -1.41 | -1.84 |
| 60 Days Ago | -0.41 | -0.41 | -1.41 | -1.84 |
| 90 Days Ago | -0.39 | -0.39 | -1.44 | -1.79 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | PSTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -17.10% | -- | -- | 5.10% |
| Next Qtr. | -51.90% | -- | -- | 11.80% |
| Current Year | -2.90% | -- | -- | 2.10% |
| Next Year | -30.50% | -- | -- | 12.30% |
| Next 5 Years (per annum) | 2.70% | -- | -- | 11.68% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 10/30/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 10/17/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/6/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 7/25/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/22/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/2/2024 |
Related Tickers
LXEO Lexeo Therapeutics, Inc.
7.93
+0.38%
NKTX Nkarta, Inc.
3.1900
+3.57%
LVTX LAVA Therapeutics N.V.
1.9000
+4.97%
CNTX Context Therapeutics Inc.
2.2700
+4.13%
IPSC Century Therapeutics, Inc.
1.2600
+9.57%
RARE Ultragenyx Pharmaceutical Inc.
50.99
0.00%
PLRX Pliant Therapeutics, Inc.
14.52
+3.20%
ERAS Erasca, Inc.
2.7200
+5.02%
OABI OmniAb, Inc.
4.1800
+2.20%
PEPG PepGen Inc.
6.48
-2.11%